BTK and B-cell chronic lymphocytic leukemia: Liso-cel has recently undergone accelerated approval by the FDA for the treatment of CLL in patients who have received at least two prior lines of therapy (including a BTK inhibitor and a BCL-2 inhibitor) [52].